Contact the Editorial Desk

Editorial correspondence

RegenLife Peptides welcomes correspondence on the research record: a citation quoted inaccurately, a newly published study on BPC-157, GHK-Cu, TB-500, or GHK, or a regulatory update that changes an approval or anti-doping status. This class of correction is the most useful message this desk receives, and each is read carefully.

The most actionable submissions specify the page in question, the exact passage being corrected or challenged, and the supporting reference — a DOI or PubMed identifier wherever possible. That format allows a proposed change to be verified against its source before it is acted on.

Editorial mailbox: editors@regenlifepeptides.com

What this desk cannot do

So no message goes unanswered for the wrong reason: RegenLife Peptides is a literature briefing, not a clinical service or product vendor. It cannot advise on or recommend human use of any peptide discussed here, suggest a dose or schedule for any individual, evaluate whether a finding from a cited study applies to a specific person's situation, or sell, source, or help locate any compound from any supplier. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.